5 July 2019 - Three-quarters of new drugs get an expedited regulatory review, thrusting families and doctors into a new world of trade-offs.

For decades, most drugs for critical illnesses passed through a standard battery of tests before regulators allowed them onto the market. A smaller portion were “fast tracked” to make them available to patients sooner.

Now that dynamic has flipped. Most drugs are released faster than ever through federal programs expediting their approval.

Read Wall Street Journal article